Our data now demonstrate the ability of calcitriol to affect the CD46 pathway and suggest that it can restore a correct IL-10:IFNγ ratio upon CD46 costimulation in CD4+ T cells from MS patients. This evidence concerns the gene CD46 and myeloid sarcoma.